Skip to main content
SpringerLink
Log in

Vermijden van onttrekkingsverschijnselen van fentanylpleisters

  • NASCHOLING
  • Published:
Huisarts en wetenschap Aims and scope

Samenvatting

Maathuis MHJ, Dijkstra DDP. Vermijden van onttrekkingsverschijnselen van fentanylpleisters. Huisarts Wet 2012;55(11):522-4.

De laatste jaren schrijven huisartsen steeds vaker fentanylpleisters voor in het kader van de behandeling van maligne en nietmaligne chronische pijn. Met een toenemende prevalentie van fentanylgebruikers krijgen huisartsen vaker dan voorheen te maken met patiënten bij wie deze pleisters om uiteenlopende redenen moeten worden afgebouwd. Tijdens dit proces kunnen forse onttrekkingsverschijnselen optreden, ook in gevallen waarbij huisartsen zorgvuldig en volgens de instructies van de fabrikant handelen. We gaan in op de processen die ten grondslag liggen aan deze onttrekkingsverschijnselen en doen een voorstel voor meer maatwerk in het afbouwen van fentanylpleisters.

Abstract

Maathuis MHJ, Dijkstra DDP. Avoidance of withdrawal symptoms with fentanyl patches.Huisarts Wet 2012;55(11):522-4.

Fentanyl patches are being used increasingly often in the treatment of malignant and non-malignant chronic pain. As a result, general practitioners often have to manage patients with severe withdrawal symptoms because their fentanyl prescription has been discontinued for whatever reason. These symptoms can arise even though GPs have followed the drug tapering instructions provided by the manufacturer. This article describes the mechanisms underlying withdrawal symptoms and proposes a more customized tapering regimen for fentanyl patches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figuur

Literatuur

  1. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008;11:S133-53.

    Google Scholar 

  2. McQuay H. Opioids in pain management. Lancet. 1999;353:2229-32.

    Article  PubMed  CAS  Google Scholar 

  3. Stanley TH. The history and development of the fentanyl series. J Pain Symptom Manage 1992;7:S3-7.

    Article  Google Scholar 

  4. Holley FO, Van Steennis C. Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. Br J Anaesth 1988;6:608-13.

    Article  Google Scholar 

  5. Farmacotherapeutisch kompas. Amstelveen: Prelum Uitgevers, 2012.

  6. Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol 2009;5:230-41.

    Article  PubMed  Google Scholar 

  7. Le Loët X, Pavelka K, Richarz U. Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study. BMC Musculoskelet Disord 2005;6:31.

    Article  PubMed  Google Scholar 

  8. Allan L, Hays H, Jensen NH, De Waroux BL, Bolt M, Donald R, et al. Randomised crossover trial of transdermal fentanyl and sustained re- lease oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1154-8.

    Article  PubMed  CAS  Google Scholar 

  9. Breekveldt-Postma NS, Penning-van Beest FJA, Herings RMC. Utilisation patterns of fentanyl transdermal system in the Netherlands. Pharmacoepidemiol Drug Saf 2005;14:129-34.

    Article  PubMed  CAS  Google Scholar 

  10. Maathuis MH, Dijkstra DD. Disaster after the plaster. Fentanyl withdrawal symptoms in a curable hospice patient. Eur J Gen Pract 2011;17:229-32.

    Article  PubMed  Google Scholar 

  11. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349:1943-53.

    Article  PubMed  CAS  Google Scholar 

  12. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management: Stepping up the quality of its evaluation. JAMA 1995;274:1870-3.

    Article  PubMed  CAS  Google Scholar 

  13. Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag 2006;1:277-82.

    Google Scholar 

  14. Bannister K, Dickenson AH. Opioid hyperalgesia. Curr Opin Support Palliat Care 2010;4:1-5.

    Article  PubMed  Google Scholar 

  15. Ishihara C, Konishi H, Chiba M, Minouchi T, Endo Y, Yamaji A. Withdrawal symptom after discontinuation of transdermal fentanyl at a daily dose of 0.6 mg. Pharm World Sci 2005;1:13-5.

    Article  Google Scholar 

  16. Bailey JA, Hurley RW, Gold MS. Crossroads of pain and addiction. Pain Med 2010;11:1803-18.

    Article  PubMed  Google Scholar 

  17. Katz R, Kelly HW, Hsi A. Prospective study on the occurrence of withdrawal in critically ill children who receive fentanyl by continuous infusion. Crit Care Med 1994;22:763-7.

    Article  PubMed  CAS  Google Scholar 

  18. Scholz J, Steinfath M, Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clin Pharmacokinet 1996;31:275-92.

    Article  PubMed  CAS  Google Scholar 

  19. Lugo RA, MacLaren R, Cash J, Pribble CG, Vernon DD. Enteral methadone to expedite fentanyl discontinuation and prevent opioid abstinence syndrome in the PICU. Pharmacotherapy 2001;21:1566-73.

    Article  PubMed  CAS  Google Scholar 

  20. Ashburn MA, Staats PS. Management of chronic pain. Lancet 1999;353:1865-9.

    Article  PubMed  CAS  Google Scholar 

  21. Kieffer BL, Evans CJ. Opioid tolerance-in search of the holy grail. Cell 2002;108:587-90.

    Article  PubMed  CAS  Google Scholar 

  22. Benich JJ. Opioid dependence. Prim Care 2011;38:59-70.

    Article  PubMed  Google Scholar 

  23. Strain EC, Stitzer ML. The treatment of opioid dependence. Baltimore (MD): Johns Hopkins Press; 2006:275-94.

    Google Scholar 

  24. Bucknall AB, Robertson JR. Heroin misuse and family medicine. Fam Pract 1985;2:244-51.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Afdeling Eerstelijnsgeneeskunde, UMC St. Radboud, 9101, 6500 HB, Nijmegen, The Netherlands

    Hugo Maathuis

  2. Meander Medisch Centrum, Amersfoort, The Netherlands

    Daniel Dijkstra

Authors
  1. Hugo Maathuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Dijkstra
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

vervolgopleiding tot huisarts, arts in opleiding tot specialist huisartsgeneeskunde, anesthesioloog

Correspondentie: h.maathuis@elg.umcn.nl

Mogelijke belangenverstrengeling: niets aangegeven.

About this article

Cite this article

Maathuis, H., Dijkstra, D. Vermijden van onttrekkingsverschijnselen van fentanylpleisters. HUISARTS WETENSCHAP 55, 522–524 (2012). https://doi.org/10.1007/s12445-012-0258-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12445-012-0258-5

Search

Navigation